T1	p 77 106	anemic patients with cancer .
T2	p 222 275	patients with cancer-associated anemia . PATIENTS AND
T3	p 284 306	Eligible patients were
T4	p 571 659	Three hundred sixty-five patients were enrolled . One hundred eighty-three patients were
T5	i 59 73	erythropoietin
T6	i 138 150	epoetin alfa
T7	i 205 217	epoetin alfa
T8	i 372 408	epoetin alfa 40,000 U subcutaneously
T9	i 411 413	SC
T10	i 437 467	standard weekly epoetin alfa (
T11	i 494 508	epoetin alfa (
T12	i 520 522	SC
T13	i 1544 1556	epoetin alfa
T14	i 1751 1763	epoetin alfa
T15	o 757 802	proportion of patients requiring transfusions
T16	o 1150 1152	Hb
T17	o 1163 1261	higher mean end-of-study Hb levels . Toxicities , including thromboembolism , and overall survival
T18	o 1314 1344	global quality of life ( QOL )
T19	o 1426 1436	global QOL